← Back to Search

Technology-Enhanced Communication for Multiple Sclerosis

N/A
Waitlist Available
Led By Ellen Mowry
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Starting one of the following MS therapies: injectable (subcutaneous interferon beta or glatiramer acetate) or oral (fingolimod, teriflunomide, or dimethyl fumarate) therapies
Expanded Disability Status Scale (EDSS) score of 6.0 or less
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 96 weeks
Awards & highlights

Study Summary

This trial will help create a questionnaire to confirm relapses in MS patients and study if communication with providers improves patient care.

Who is the study for?
This trial is for English-speaking individuals with relapsing-remitting MS who have had at least two relapses in the past two years or one recent onset of RRMS. Participants must own a smartphone or be willing to use one, live within 100 miles of Johns Hopkins Medical Center, and have an EDSS score of 6.0 or less.Check my eligibility
What is being tested?
The study aims to develop a questionnaire that can confirm MS relapses without needing an office visit. It will also assess if better communication with healthcare providers via technology improves patient care and satisfaction.See study design
What are the potential side effects?
Since this trial focuses on communication improvements rather than medication, there are no direct side effects from interventions being tested. However, participants may experience general discomfort related to their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am starting a new MS therapy, either an injection or a pill.
Select...
My disability level allows me to walk at least 100 meters without aid or rest.
Select...
I have been diagnosed with relapsing-remitting MS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~96 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 96 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blinded

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
A different kind of communication with the clinic will be used.
Group II: ControlActive Control1 Intervention
One kind of communication with the clinic will be used.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,259 Previous Clinical Trials
14,820,503 Total Patients Enrolled
30 Trials studying Multiple Sclerosis
2,487 Patients Enrolled for Multiple Sclerosis
Ellen MowryPrincipal InvestigatorJohns Hopkins University

Media Library

Communication with the clinic Clinical Trial Eligibility Overview. Trial Name: NCT02454907 — N/A
Multiple Sclerosis Research Study Groups: Experimental, Control
Multiple Sclerosis Clinical Trial 2023: Communication with the clinic Highlights & Side Effects. Trial Name: NCT02454907 — N/A
Communication with the clinic 2023 Treatment Timeline for Medical Study. Trial Name: NCT02454907 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is this research trial recruiting participants?

"Affirmative. The information hosted on clinicaltrials.gov establishes that this medical experiment, which was initially posted on July 31st 2018 is currently recruiting patients. 150 participants must be recruited from a single study site."

Answered by AI

Is it still possible to participate in this research endeavor?

"Affirmative. On clinicaltrials.gov, it is noted that this examination commenced its recruitment of participants on July 31st 2018 and was last modified on May 5th 2022. The trial aims to enlist 150 individuals from a single medical location."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The Use of Technology to Improve MS Clinical Trials and Patient Care
2018. "The Use of Technology to Improve MS Clinical Trials and Patient Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02454907.
All > Multiple Sclerosis
~31 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top